Drug Trial Radar · NCT07609862
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
92
Planned (sponsor's estimate)
Start
Jul 14, 2026
Primary completion
Jun 30, 2029
Study completion May 30, 2033
Sponsor
- Lead sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.Industry
- Sponsor type
- Industry
- First posted
- May 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
BTK inhibitors and BCL-2 inhibitors have demonstrated significant clinical activity in mature B-cell malignancies, and combination therapy may provide improved clinical benefit. This is a multi-center, open-label, single-arm Phase Ib/II clinical study. The purpose of this clinical trial is to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of Rocbrutinib, a fourth-generation Bruton tyrosine kinase inhibitor (BTKi), in combination with the BCL-2 inhibitor Lacutoclax in patients with mature B-cell malignancies. The Phase Ib will use a classic 3+3 dose-escalation design to evaluate dose-limiting toxicities (DLTs), determine the maximum tolerated dose (MTD), and identify the recommended dosing regimen. The Phase II portion is intended to further evaluate the efficacy and safety of the combination therapy.
Conditions
- Mantle Cell Lymphoma (MCL)
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Follicular Lymphoma ( FL)
- Waldenström Macroglobulinemia (WM)
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Interventions
Lacutoclax+RocbrutinibDrug
Phase Ib dose-escalation study of Rocbrutinib in combination with Lacutoclax. Rocbrutinib will be administered at a fixed dose of 150 mg once daily (QD), while Lacutoclax will be dose-escalated. Initial dose levels include Lacutoclax 200 mg QD and 400 mg QD in 28-day treatment cycles.Treatment will continue until disease progression, unacceptable toxicity/intolerance, or completion of the protocol-defined treatment duration, whichever occurs first. In phase II, participants will receive Rocbrutinib monotherapy for 8-12 weeks prior to combination treatment. Upon initiation of combination therapy, Lacutoclax will undergo dose ramp-up to the target dose and will then be administered continuously at the target dose. Treatment will continue until disease progression, unacceptable toxicity/intolerance, or completion of the protocol-defined treatment duration, whichever occurs first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: Dose-limiting toxicity (DLT)Time frame: At the end of Cycle 1 (the length of cycle 1 is 28 days)
- Phase Ib: Maximum Tolerated Dose (MTD)Time frame: At the end of Cycle 1 (the length of cycle 1 is 28 days)
- Phase Ib: Adverse events as assessed by CTCAE v5.0Time frame: From the first administration to 28 days after the last administration
- Phase Ib: Time to Maximum Plasma Concentration (Tmax)Time frame: From 1 hour prior to administration to 24 hours post-dose
- Phase Ib: Maximum Plasma Concentration (Cmax)Time frame: From 1 hour prior to administration to 24 hours post-dose
- Phase Ib: Area Under the Plasma Concentration-Time Curve from Time Zero to Time t (AUC0-t)Time frame: From 1 hour prior to administration to 24 hours post-dose
- Phase Ib: Half-life (t1/2)Time frame: From 1 hour prior to administration to 24 hours post-dose
- Phase II: Undetectable minimal residual disease (uMRD) rate assessed by flow cytometryTime frame: Up to approximately three years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.